Ms.
Alter profiles seven stocks that could get a boost following the 2014 Annual
Meeting of the American Society of Clinical Oncology (ASCO), including one company
with a drug that in a recent study showed a reduction in the risk of the
patients’ death by 57%.
Disclaimer: This article was posted with the permission
of a third-party contributor and the opinions contained therein do not
necessarily reflect those of Smallcappower. Smallcappower does not endorse
any investment advice provided by these third-party contributors. Please
consult your investment advisor before making any investment
decisions.
Ubika Corporation and its divisions Smallcappower, Ubika
Communication and Ubika Research are not registered with any financial or
securities regulatory authority in Ontario or Canada, and do not provide
nor claims to provide investment advice or recommendations to any visitor of
this site or readers of any content on this site. – See more at: http://www.smallcappower.com/posts/small-cap-power-disclosure
